secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310472
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC presents enozertinib Phase 1b update; no specific results in filing
------------------------------------------------------------------------

- Company announced enozertinib (ORIC-114) program update on December 6, 2025.
- Update covers data from Phase 1b trial; presentation attached as Exhibit 99.1.
- No efficacy or safety figures included in the filing text itself.
- Investors must refer to the separate presentation for detailed data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525310472/0001193125-25-310472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312525310472/d46273d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer